Adicet Bio (ACET) Expected to Announce Quarterly Earnings on Wednesday

Adicet Bio (NASDAQ:ACET) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Adicet Bio to announce earnings of ($1.56) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Adicet Bio (NASDAQ:ACET) last released its earnings results on Wednesday, August 5th. The company reported ($1.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.30). On average, analysts expect Adicet Bio to post ($6.76) EPS for the current fiscal year and ($5.64) EPS for the next fiscal year.

Adicet Bio Stock Performance

Adicet Bio stock opened at $3.81 on Wednesday. Adicet Bio has a 12-month low of $3.77 and a 12-month high of $14.56. The firm has a 50-day moving average price of $7.49 and a 200-day moving average price of $7.76.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adicet Bio in a report on Friday, August 21st. Guggenheim reissued a “buy” rating and issued a $90.00 price objective (down from $100.00) on shares of Adicet Bio in a research note on Thursday, August 6th. Wall Street Zen downgraded shares of Adicet Bio from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. HC Wainwright boosted their target price on Adicet Bio from $27.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, September 28th. Finally, Wedbush restated an “outperform” rating and set a $28.00 target price (up from $25.00) on shares of Adicet Bio in a research report on Monday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Adicet Bio currently has an average rating of “Moderate Buy” and an average price target of $37.80.

About Adicet Bio

Adicet Bio, Inc is a clinical-stage biotechnology company developing allogeneic T-cell therapies for the treatment of cancer. The company’s platform is focused on genetically engineered gamma delta T cells, an immune-cell type that can recognize and attack abnormal cells while potentially offering advantages for off-the-shelf cell therapy development.

Adicet’s product candidates are designed to incorporate chimeric antigen receptors and other modifications intended to improve tumor targeting, persistence, and activity.